Business
CSL ‘cautious’ on profit outlook even after vaccines boosted half-year results – Sydney Morning Herald
Australia’s local maker of AstraZeneca Oxford’s COVID-19 jabs beat market expectations as sales of its seasonal influenza vaccines soared in the face of COVID-19,…
The full-year result will be heavily skewed to the first half, he told analysts. The impacts of COVID, both positive and negative, add a pretty heavy layer of complexity and uncertainty to our earnings profile until we get through this pandemic.
CSL maintained its previous earnings guidance, predicting profits of between $2.17 and $2.27 billion for the 2021 financial year. Asked why the $131 billion biotech wasnt increasing its forecasts, Mr Perreault highlighted that because of the seasonal nature…
-
Noosa News23 hours agoWhat led to the giant, damaging hail which smashed parts of Queensland over the weekend?
-
General16 hours agoMan who shot poodle in Central Coast caravan park robbery sentenced to eight years in prison
-
Business19 hours agoMacquarie tips 40%+ upside for this ASX mining stock
-
Noosa News22 hours agoRescuers save grey nurse shark off North Stradbroke Island, Queensland